IntriCon Corporation (NASDAQ:IIN) is at an overbought level with an RSI(14) at 82.52.
The Relative Strength Index (RSI) is one of the most popular technical indicators used to determine strengthening and weakening momentum in stock price. An RSI above 70 is considered overbought with RSI’s under 30 indicating oversold. Overbought is a condition that occurs when prices are considered too high and susceptible to a decline.
(NASDAQ:IIN) currently has a beta of 0.12 so it is less volatile than the market overall which by definition has a beta of 1. Stocks with a beta lower than the market are less risky and those with a higher beta may be more risky than the market.
The stock’s Average True Range (ATR) is sitting at 0.54. The ATR is a measure of volatility. A high or low ATR doesn’t tell you which way a stock will move but is a signal that it is likely to move.
Company shares are trading at $12.88 which is well above $9.16, the stock’s 50 day moving average and which is quite a bit above the 200 day moving average of $8.47. The 50 day moving average was up $3.72 or +40.6137% and the 200 day average went up by +52.0042%.
Investors are more bullish on IntriCon Corporation as evidenced by the downtick in short interest. The firm realized a fall in short interest of -25.77% as of the latest report on August 31, 2017. Short shares fell from 18,071 to 13,415 over that period. With short interest at 13,415 and short average daily volume at 12,046, days to cover is 1.0 and the percentage of shorted shares was 0.00% on August 31.
Here is a rundown on some insider market activity for IntriCon Corporation (NASDAQ:IIN). VP Sales and Marketing Michael Geraci disclosed the sale of 2,887 shares of (IIN). The shares were purchased at an average price of $9.00. The VP Sales and Marketing now owns $209,628 of the stock per the Form 4 SEC filing.
In the latest earnings report the EPS was $-0.43 and is expected to be $0.34 for the current year with 6,850,000 shares currently outstanding. Next quarter’s EPS is forecasted at $0.08 with next year’s EPS projected to be $0.41.
IntriCon Corporation, launched on June 24, 1930, is involved in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market. The Company has facilities in Minnesota, California, Singapore, Indonesia, the United Kingdom and Germany, and operates through its subsidiaries. The Business’s product offering includes a hearing aid discount program for health plans. This program is available around the nation to health insurers, including employer-sponsored, individual and Medicare plans. The Company also has various international value hearing aid (VHA) initiatives. In the medical bio-telemetry market, the Company is focused on sales of bio-telemetry devices for life-critical diagnostic monitoring. Using its nanoDSP and BodyNet technology platforms, the Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and bio-telemetry devices for medical device manufacturers..